Table 2.
Sunitinib + mFOLFOX6 (n=96) | Bevacizumab + mFOLFOX6 (n=95) | |
---|---|---|
Complete response, n (%) | 1 (1.0) | 1 (1.1) |
Partial response, n (%) | 38 (39.6) | 35 (36.8) |
Stable disease, n (%) | 44 (45.8) | 53 (55.8) |
Progressive disease, n (%) | 3 (3.1) | 1 (1.1) |